CORDIS
EU research results

CORDIS

English EN

Proof of concept of prognostic test for critical Septic Patients based in Early Detection of NLRP3 Inflammasome impairment activation.

Project information

Grant agreement ID: 899636

Status

Grant agreement signed

  • Start date

    1 September 2020

  • End date

    28 February 2022

Funded under:

H2020-EU.1.1.

Hosted by:

FUNDACION PARA LA FORMACION E INVESTIGACION SANITARIAS DE LA REGION DE MURCIA

Spain

Objective

Sepsis remains the leading cause of death in critical care units of Hospitals, affecting more that 18 million people worldwide and causes a systemic inflammatory response driven by the production of proinflammatory cytokines. Several studies have been conducted to find out whether data mining and machine learning could be used to identify patients at risk of sepsis. Although the currently available biomarkers can help shorten this decision process, there is still a need for additional early disease biomarkers that could anticipate the decision-making identifying immunocompromised septic patients. In this sense, ongoing efforts in the development of a point-of-care testing kit, enabling quick and reliable detection of immunocompromised patients by using blood biomarkers, will aid greatly the early prognosis of sepsis. In this scenario, the prognosis and therapy selection still remains a clinical decision by assessing the patient’s history, symptoms of infection, and development of acute organ dysfunction. Our group have determined under the ERC consolidator grant ref. 614578 (DangerATP) that during the initial 24 h of the inflammatory response in sepsis, monocytes from human septic patients present an early impairment of the activation of the NLRP3 inflammasome that is associated with higher late mortality. This group of septic patients was not identified with any of the clinical or biochemical determinations performed.
We have developed an in vitro prognostic (IVD) product for the fast detection in less than 4 hours of early impairment of the NLRP3 inflammasome activation, as a biomarker for the prognosis in sepsis. This IVD will be used in intensive care units and immunology units of hospitals. The objective of the action is to demonstrate the technical and commercial feasibility and evaluate the new business opportunity of introducing this novel IVD product.

Host institution

FUNDACION PARA LA FORMACION E INVESTIGACION SANITARIAS DE LA REGION DE MURCIA

Address

Calle Luis Fontes Pagan 9 Edif Emi Hospital Reina Sofia
30003 Murcia

Spain

Activity type

Research Organisations

EU Contribution

€ 150 000

Beneficiaries (1)

FUNDACION PARA LA FORMACION E INVESTIGACION SANITARIAS DE LA REGION DE MURCIA

Spain

EU Contribution

€ 150 000

Project information

Grant agreement ID: 899636

Status

Grant agreement signed

  • Start date

    1 September 2020

  • End date

    28 February 2022

Funded under:

H2020-EU.1.1.

Hosted by:

FUNDACION PARA LA FORMACION E INVESTIGACION SANITARIAS DE LA REGION DE MURCIA

Spain